Here are the 424B prospectus supplements from Denali Capital Acq CP A (DNQAF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DNQAF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNQAF filings page.
Semnur Pharmaceuticals, Inc. has filed a shelf registration covering the potential resale by existing holders of up to 203,737,349 shares of common stock, plus up to 510,000 private warrants, and the issuance of up to 8,760,000 shares upon exercise of outstanding public and private warrants. The company will receive cash only if these warrants are exercised, and will not receive proceeds from any secondary sales by the selling securityholders.
Semnur is a late-stage clinical biopharmaceutical company focused on non-opioid pain management, led by its Phase 3 product candidate SP‑102, an injectable dexamethasone viscous gel being developed for sciatica. The business recently completed a SPAC business combination with Denali Capital Acquisition Corp., becoming a Delaware corporation whose common stock and public warrants trade on the OTC Pink market as “SMNR” and “SMNRW.”
The company has no approved products, has incurred substantial losses (including a net loss of $154.3 million for the nine months ended September 30, 2025) and carries an accumulated deficit of $269.6 million, with auditors and management disclosing substantial doubt about its ability to continue as a going concern. Semnur’s prospects depend heavily on successfully completing additional trials, obtaining regulatory approval and securing financing to advance and commercialize SP‑102.